Please use this identifier to cite or link to this item: https://hdl.handle.net/1/2023
Title: Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance
Authors: Armytage, Tasman ;Wight, J.;Hamad, N.;Campbell, B. A.;Ku, M.;Lee, K.;Rose, H.;Latimer, M.;Lee, H. P.;Lee, S. T.;Dickinson, M.;Khor, R.;Verner, E.
Affliation: Central Coast Local Health District
Gosford Hospital
Issue Date: 16-Sep-2021
Source: 52(9):1609-1623
Journal title: Internal Medicine Journal
Department: Haematology
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though aggressive, cure is achievable in approximately 60% of cases with primary chemo-immunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, CNS prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice. This article is protected by copyright. All rights reserved.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/2023
DOI: 10.1111/imj.15533
Pubmed: https://pubmed.ncbi.nlm.nih.gov/34532916/
ISSN: 1444-0903
Publicaton type: Journal Article
Keywords: Cancer
Appears in Collections:Oncology / Cancer

Show full item record

Page view(s)

32
checked on Jan 27, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.